Recent evidence suggests that gastrointestinal side effects are usually temporary and resolve with time, while the risk for pancreatitis, gallbladder disease and hypoglycaemia appears comparable to GLP‐1 receptor agonists. This evidence concerns the gene GLP1R and gallbladder disorder.